Biomedical subjects

Ines Lanzl

Publications and source records attributed to Ines Lanzl.

4 recordsLinked to original sources

PubMed2005

Dorzolamide influences the autoregulation of major retinal vessels caused by artificial intraocular pressure elevation in patients with POAG: a clinical study.

PURPOSE: The study investigated whether dorzolamide influences the autoregulatory behavior of major retinal arterioles in glaucoma patients via a moderate perfusion pressure reduction. METHODS: The study included one eye each of 12 untreated patients with a primary open-angle glaucoma (POAG) (age 60.8 +/- 8.3, IOP 22.3 +/- 6.5 mmHg). Changes in the diameter of a retinal artery segment before (120 s), during (100 s), and after (380 s) artificial IOP elevation to 38 mmHg for 100 s were recorded continuously by means of a Retinal Vessel Analyzer. The measurement was repeated after 4-week treatment with dorzolamide eye drops t.i.d. RESULTS: Ocular perfusion pressure (mmHg) was reduced by the intraocular pressure (IOP) elevation from 58 (+/- 10) to 41 (+/- 11) in the pretreatment examination and from 60 (+/- 8) to 40 (+/- 8) posttreatment (differences between the examinations n.s.). Before IOP elevation, the arterial diameter was found to be +1.7 +/- 3.5% greater in the posttreated eyes than in the pretreated eyes (p < 0.02). During IOP elevation, the arterial diameter decreased by -1.8% +/- 3.8 in the pretreated eyes, whereas dilatation by +1.4% +/- 2.5 was observed in the posttreated eyes (p = 0.02). At the end of the observation period following IOP elevation, the vessel diameter in the pretreated eyes had increased by +1.8% +/- 4.2, whereas in the posttreated eyes it had decreased by -1.7% +/- 3.0. On average, dorzolamide reduced IOP by -5.6 mmHg (p = 0.001). CONCLUSIONS: The arterial diameter dilatation during IOP elevation in dorzolamide-treated eyes could be an accelerated counter-regulation on the induced elevated IOP and could constitute an additional therapeutic effect.

Aged↗

PubMed2004

Age, blood pressure, and vessel diameter as factors influencing the arterial retinal flicker response.

PURPOSE: The present study investigated whether age, blood pressure (BP), and baseline vessel diameter influence the retinal arterial response to flicker light. METHOD: Thirty healthy subjects (mean age, 46.3; range, 22-73 years) and 15 patients with untreated essential arterial hypertension (mean, 50.9; range, 26-69 years) were examined. The diameter of the retinal arterioles was measured by a Retinal Vessel Analyzer (RVA; Imedos, Weimar, Germany). Each examination consisted of a 100-second baseline measurement and five 20-second periods of flicker stimulation, followed by an 80-second observation period. The five stimulation periods were then averaged. The rectangular luminance flicker operated at 12.5 Hz at a wavelength of 530 to 600 nm. The baseline-corrected flicker response (bFR) was defined as the difference between the peak dilatation and subsequent constriction after flicker stimulation minus the fluctuation of the baseline. The BP was measured at 1-minute intervals during the examination. RESULTS: In 26 subjects with normal BP, flicker light induced a bFR of +6.4% +/- 2.7%. The bFR decreased nonsignificantly in healthy subjects with increasing age (y = 8.48-0.048x; r = 0.26). The baseline diameter did not influence the amplitude of the flicker response over a range of 70 to 140 measuring units. The hypertensive patients reacted with a bFR of +2.2% +/- 2.5% (P < 0.001). Four hitherto healthy subjects with elevated BP during the examination were excluded from analysis. CONCLUSIONS: A significant correlation of age and bFR was not found in the small sample examined. Untreated arterial hypertension appeared to be associated with a reduced flicker response. The value of such functional vessel properties in the screening of vasosclerosis and in diagnostics in arterial hypertension should be examined in further studies.

Adult↗

PubMed2003

Oligosymptomatic cornea verticillata in a heterozygote for Fabry disease: a novel mutation in the alpha-galactosidase gene.

BACKGROUND: Fabry disease is an X-linked genetic disorder involving sphingolipid catabolism, which is caused by lysosomal alpha-galactosidase A deficiency. Ophthalmological findings such as corneal and lens opacities and conjunctival and retinal vessel abnormalities can be the only and/or the first recognizable symptoms, especially in heterozygous females. METHODS: We report on a 34-year-old German woman with cornea verticillata. The alpha-galactosidase A activity was determined in leukocytes using a fluorescence substrate, and the sequence analysis of the alpha galactosidase A gene was performed with genomic DNA. RESULTS: The alpha-galactosidase A activity in leukocytes was significantly low (0.24 nmol/min/mg protein; normal range, 0.4-1.2), which is compatible with a heterozygote for Fabry disease. The following sequence analysis revealed a heterozygous transition in position IVS5 + 2 T > C. Transition of thymine (T) to cytosine (C) affects the donor splice motive of exon 5 and most probably leads to an aberrant splicing procedure of the alpha-galactosidase A gene. CONCLUSION: Our case emphasizes the importance of ophthalmological findings in Fabry disease. The subsequent biochemical and molecular analysis provides a secure diagnosis of female carriers of Fabry disease.

Adult↗

PubMed2003

Online human conjunctival vessel diameter analysis. A clinical-methodical study.

BACKGROUND: The present study investigates the possible application of a commercially available on-line measuring device of retinal vessels for conjunctival vessel assessment. METHODS: Repeated measurements in one randomly chosen eye were performed in 11 healthy volunteers (mean age 42.9 +/- 10 years). Measurements of one conjunctival vessel were obtained first without a stimulus followed by measurements after the application of one drop of a topical vasoconstrictor. The examinations were performed by Retinal Vessel Analyzer (RVA, IMEDOS/Germany). This system determines automatically on-line the vessel diameter along a chosen vessel segment. RESULTS: Measurements in the native state without eye drop application showed an intraclass correlation coefficient of 0.97 and a mean variation coefficient of 1.8%. After application of the topical vasoconstrictor a short acting vasodilatation was observed with a magnitude of +10.9% +/- 14.9 (p < 0.001), followed by an increasing vasoconstriction (after 4 min -12.0% +/- 7.6; p = 0.004). One volunteer had no measurable conjunctival vessels in the baseline measurements and was therefore excluded from the study. DISCUSSION: The suggested technique allows the measurement of changes in conjunctival vessel diameter with high precision. The method represents a non invasive technique for the assessment of effects on conjunctival vessels caused by topical or systemic drugs.

Adult↗